Jump to content

User:Mr. Ibrahem/Vericiguat

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Vericiguat
Clinical data
Trade namesVerquvo
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classSoluble guanylate cyclase activator
Legal status
Legal status
Identifiers
  • methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
Chemical and physical data
FormulaC19H16F2N8O2
Molar mass426.388 g·mol−1
3D model (JSmol)
  • COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
  • InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
  • Key:QZFHIXARHDBPBY-UHFFFAOYSA-N

Vericiguat, sold under the brand name Verquvo, is a medication used in heart failure after a recent worsening to reduce the risk of heart related death and hospitalization.[3][5] It is only used in those with an ejection fraction less than 45%.[3] It is taken by mouth.[5]

Common side effects include low blood pressure and low red blood cells.[4][5] Use in pregnancy may harm the baby.[4] It is a soluble guanylate cyclase (sGC) stimulator, and should not be used with other medications in this class.[3][5]

Vericiguat was approved for medical use in the United States and Europe in 2021.[4][5] In the United States it costs about 615 USD per month as of 2022.[6] This amount in the United Kingdom costs the NHS about £100.[7]

References[edit]

  1. ^ a b "Verquvo". Therapeutic Goods Administration (TGA). 29 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.
  2. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
  3. ^ a b c d e f "Verquvo- vericiguat tablet, film coated". DailyMed. Archived from the original on 6 September 2021. Retrieved 9 February 2021.
  4. ^ a b c d e "Drug Trials Snapshot: Verquvo". U.S. Food and Drug Administration (FDA). 8 February 2021. Archived from the original on 9 February 2021. Retrieved 8 February 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ a b c d e f g h "Verquvo EPAR". European Medicines Agency (EMA). 19 May 2021. Archived from the original on 15 September 2021. Retrieved 14 September 2021.
  6. ^ "Verquvo". Archived from the original on 23 October 2022. Retrieved 23 October 2022.
  7. ^ "Vericiguat". SPS - Specialist Pharmacy Service. 17 October 2016. Archived from the original on 3 March 2022. Retrieved 23 October 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Vericiguat&oldid=1199153596"